Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia

Abstract

Fludarabine is an antineoplastic agent used in the treatment of hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and indolent B-cell lymphoma. Because of its immunosuppressive effects, fludarabine has been added to reduced intensity conditioning regimens. The oral formulation of fludarabine has become widely available. Pharmacokinetic studies have shown that an oral dose of 40 mg/m2/d would provide systemic drug exposure similar to the standard intravenous (IV) dose of 25 mg/m2/d. The oral dose can be taken once daily without any dietary restrictions. Dose adjustments are mandatory in patients with renal impairment to avoid increased toxicity. Several noncomparative trials in previously untreated and treated patients with CLL have shown that treatment with the oral formulation demonstrates similar efficacy compared to historical control groups treated with the IV formulation. The tolerability profile of oral fludarabine seems similar to that of the IV formulation. Myelosuppression and infectious complications are the most frequently reported adverse events. Gastrointestinal toxicity is more frequent with the oral formulation, but is usually of mild or moderate severity. Although oral fludarabine makes treatment more convenient, health care workers must be aware of the compliance behavior of each patient.

Trending Drugs Combination to Target Leukemia associated Proteins/Genes: using Graph Neural Networks under the RAIN Protocol

“…Fludarabine, an antineoplastic drug, is widely employed in the management of hematological malignancies, specifically chronic lymphocytic leukemia (CLL) and indolent B-cell lymphoma. Due to its ability to suppress the immune system, fludarabine has been incorporated into reduced intensity conditioning regimens [27], [117]- [119].…”

Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies

“…Chemotherapy is widely used in leukemia treatment. Poor bioavailability, shorter half-life, drug resistance, and side effects are the major limitations of chemotherapeutic drugs [121][122][123][124][125][126]. Conjugation of chemotherapeutic drugs (Figure 10) with GNMs improved selectivity, efficacy, and potency against HMs.…”

“…FLP interferes with DNA synthesis in HMs [122,124]. However, FLP has many side effects such as lymphopenia, severe autoimmune hemolytic anemia, gastrointestinal toxicity (nausea, vomiting), hair loss, and more [122][123][124]. To improve the selectivity and efficacy of FLP, Song et al [124] loaded FLU on FA-conjugated AuNPs (FLP-FA-AuNPs).…”

From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds

“…It is converted to the purine analog named F-ara-A. Its bioavailability is enhanced when it gets phosphorylated and inhibits cell proliferation through the inhibition of DNA polymerase and ribonuclease reductase [150].…”